resatorvid and Shock--Septic

New glycolipids and a benzylammonium lipid were rationally designed by varying the chemical structure of a D-glucose-derived hit compound active as lipid A antagonist. We report the synthesis of these compounds, their in vitro activity as lipid A antagonists on HEK cells, and the capacity to inhibit LPS-induced septic shock in vivo. The lack of toxicity and the good in vivo activity suggest the use of some compounds of the panel as hits for antisepsis drug development.

Topics: Anti-Infective Agents; Benzylammonium Compounds; Cell Line; Drug Design; Glycolipids; Humans; Lipid A; Lipids; Sepsis; Shock, Septic; Structure-Activity Relationship